Intec Pharma Ltd.
10 Hartom Street (Rmpe Building)
78 articles with Intec Pharma Ltd.
Intec Pharma Ltd. announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF AN AGENT," and covers Intec's gastro-retentive drug delivery device with perforated external film.
Intec Pharma Ltd. announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to explore using the Accordion Pill® platform for an undisclosed development program.
Intec Pharma Ltd. announces financial results for the three months ended March 31, 2019 and provides a corporate update.
Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders
Intec Pharma Ltd. announces that the results from a pharmacokinetics study of the Accordion Pill™-Carbidopa/Levodopa 50/500 mg dosed three times per day was accepted for presentation in a poster at the upcoming XXIV World Congress on Parkinson's Disease and Related Disorders taking place June 16-19, 2019 at the Lyon Convention Centre in Montreal, Canada.
Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients
Company on track to report top-line data in July/August time frame
Intec Pharma Ltd. announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.
Intec Pharma today announces that Company management will participate at the following upcoming investment conferences in March.
Intec Pharma Ltd. announces financial results for the fourth quarter and year ended December 31, 2018 and provides a corporate update.
Intec Pharma Reports Positive Results from Pharmacokinetic Study of Accordion Pill™ Carbidopa/Levodopa 50/500 mg Dosed Three Times Daily
AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance
Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC
Pursuing medical cannabinoids for a variety of pain indications
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma, has issued a Letter to Shareholders, the full text of which follows below.
Accordion Pill for proprietary compound achieves in-vitro specifications
Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019
Intec Pharma Ltd. today announces that Company management will participate at the following upcoming investment conferences in November.
Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society
Intec Pharma Ltd. today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson's and Movement Disorder Society (MDS 2018) being held from October 5-9, 2018 in Hong Kong.
Intec Pharma Ltd. today announces that Company management will participate at the following upcoming investment conferences.
Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study
Former LabCorp CFO Brings Wealth of Financial Experience
Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City.